These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 22946566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
    de Oliveira Lopes R, Romeiro NC, de Lima CK, Louback da Silva L, de Miranda AL, Nascimento PG, Cunha FQ, Barreiro EJ, Lima LM.
    Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis and Biological Evaluation of Novel Substituted N,N'-Diaryl ureas as Potent p38 Inhibitors.
    Zhu D, Li X, Zhong W, Zhao D.
    Molecules; 2015 Sep 11; 20(9):16604-19. PubMed ID: 26378516
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI, Khan MA, Tarazi H, Abdel-Maksoud MS, Gamal El-Din MM, Yoo KH, Oh CH.
    Eur J Med Chem; 2017 Feb 15; 127():413-423. PubMed ID: 28088086
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K, Tariq S, Amir M.
    Bioorg Chem; 2019 Jun 15; 87():550-559. PubMed ID: 30928877
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC, Fischer S, Schollmeyer D, Schattel V, Grütter C, Rauh D, Laufer SA.
    J Med Chem; 2012 Jun 28; 55(12):5868-77. PubMed ID: 22676210
    [Abstract] [Full Text] [Related]

  • 9. TAK1 inhibition in the DFG-out conformation.
    Kilty I, Green MP, Bell AS, Brown DG, Dodd PG, Hewson C, Hughes SJ, Phillips C, Ryckmans T, Smith RT, van Hoorn WP, Cohen P, Jones LH.
    Chem Biol Drug Des; 2013 Nov 28; 82(5):500-5. PubMed ID: 23745990
    [Abstract] [Full Text] [Related]

  • 10. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J, Moquin RV, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly K, Doweyko AM, Sack JS, Zhang H, Kiefer SE, Kish K, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2652-7. PubMed ID: 18359226
    [Abstract] [Full Text] [Related]

  • 11. Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives.
    Kulkarni RG, Laufer SA, M CV, Garlapati A.
    Med Chem; 2013 Feb 15; 9(1):91-9. PubMed ID: 22946527
    [Abstract] [Full Text] [Related]

  • 12. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S, Grütter C, Naqvi T, Rabiller M, Simard JR, Pawar V, Getlik M, Rauh D.
    J Med Chem; 2010 Jan 14; 53(1):357-67. PubMed ID: 19928858
    [Abstract] [Full Text] [Related]

  • 13. p38 MAP kinase inhibitors as anti inflammatory agents.
    Amir M, Somakala K, Ali S.
    Mini Rev Med Chem; 2013 Dec 14; 13(14):2082-96. PubMed ID: 24107108
    [Abstract] [Full Text] [Related]

  • 14. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A, Takahashi M, Takai T, Goto M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Hamada T, Shirasaki M, Okada K, Snell G, Bragstad K, Sang BC, Uchikawa O, Miwatashi S.
    Bioorg Med Chem; 2018 Feb 01; 26(3):647-660. PubMed ID: 29291937
    [Abstract] [Full Text] [Related]

  • 15. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
    Sabatini S, Manfroni G, Barreca ML, Bauer SM, Gargaro M, Cannalire R, Astolfi A, Brea J, Vacca C, Pirro M, Massari S, Tabarrini O, Loza MI, Fallarino F, Laufer SA, Cecchetti V.
    Chem Biol Drug Des; 2015 Oct 01; 86(4):531-45. PubMed ID: 25589097
    [Abstract] [Full Text] [Related]

  • 16. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M, Grütter C, Simard JR, Nguyen HD, Robubi A, Aust B, van Otterlo WA, Rauh D.
    Eur J Med Chem; 2012 Feb 01; 48():1-15. PubMed ID: 22154891
    [Abstract] [Full Text] [Related]

  • 17. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H, Lee S, Hong S.
    Bioorg Med Chem Lett; 2015 Sep 15; 25(18):3784-7. PubMed ID: 26259807
    [Abstract] [Full Text] [Related]

  • 18. Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies.
    Doma A, Kulkarni R, Palakodety R, Sastry GN, Sridhara J, Garlapati A.
    Bioorg Med Chem; 2014 Nov 01; 22(21):6209-19. PubMed ID: 25261929
    [Abstract] [Full Text] [Related]

  • 19. 1,2,4-Triazole-based benzothiazole/benzoxazole derivatives: Design, synthesis, p38α MAP kinase inhibition, anti-inflammatory activity and molecular docking studies.
    Tariq S, Kamboj P, Alam O, Amir M.
    Bioorg Chem; 2018 Dec 01; 81():630-641. PubMed ID: 30253336
    [Abstract] [Full Text] [Related]

  • 20. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
    Ziegler K, Hauser DR, Unger A, Albrecht W, Laufer SA.
    ChemMedChem; 2009 Nov 01; 4(11):1939-48. PubMed ID: 19731280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.